MAXHEALTHBSEMax Healthcare Institute LtdHighNeutral
Announced Thu, 21 May · 16:26 IST

Results for Fourth Quarter and Financial Year ended March 31, 2026

Pat Growth 25pctRevenue Growth 20pctExceptional ItemResults View source PDF

MAXHEALTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-8.5%1-day move
₹1093.15
prior close
₹1068.25
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.7-3.9-4.7-4.6-8.5-9.2-9.0-11.7-13.7-11.7-5.8-0.0-1.1
Up moveDown movePending
AI summary

Max Healthcare reported strong FY26 results with consolidated revenue growing 19.1% year-over-year to ₹8,37,345 lakhs. Profit after tax surged 34.1% to ₹1,44,241 lakhs, driven by the merger of Crosslay Remedies with Jaypee Healthcare (completed December 2025) which resulted in a cumulative tax benefit of ₹14,148 lakhs. EPS improved to ₹14.83 from ₹11.07. Exceptional items of ₹4,824 lakhs include ₹3,390 lakhs impact from new Labour Codes. The company also completed acquisition of 58.28% stake in Kalinga Hospitals (May 2026) for ₹29,797 lakhs and approved construction of a new 712-bed hospital in Lucknow. Auditors issued an unmodified (clean) opinion.

Likely market impact

The 34% PAT growth significantly exceeds the 25% benchmark and signals strong operational performance. However, expansion investments (Lucknow hospital, Kalinga acquisition) and higher labour costs may compress margins near-term. The clean audit opinion removes key risks. Shareholders can expect dividend of ₹2 per share subject to AGM approval.